Every 10-Q that CANNAPHARMARX INC (CPMD) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 10-Q covers the quarterly report filed between annual reports, so if you follow CPMD and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full CPMD filings page.
CannaPharmaRx, Inc. (CPMD), a Canadian cannabis cultivator, reported higher revenue but continued heavy losses and liquidity stress for the quarter and six months ended June 30, 2026. Revenue rose to $276,218 for the quarter and $903,680 for the first half of 2026, largely from related-party sales to Cantek.
The company still generated a gross loss of $138,446 for the quarter and $547,899 year-to-date, and recorded a net loss of $1,909,042 for the quarter and $2,291,063 for six months. Cash was only $555 with a working capital deficiency of $31.2 million and accumulated deficit of $114.6 million, and management explicitly states there is substantial doubt about its ability to continue as a going concern.
Operations are highly dependent on related parties: loans payable to related parties total $13.4 million, royalty and lease obligations are in default with Koze and Formosa (with Koze temporarily forbearing from enforcing its security over the main operating subsidiary), and multiple secured borrowings are in default, exposing assets to potential seizure. Insurance coverage has lapsed, and several legal matters and judgments are outstanding, while the company also continues to dilute shareholders through equity-for-debt settlements.
CannaPharmaRx, Inc. reported Q1 2026 revenue of $627,462, up from $335,319 a year earlier, but operations remained unprofitable with a net loss of $382,021 and a gross loss of $409,453.
Cash was only $633 at March 31, 2026, against a working capital deficiency of $30,556,522, total liabilities of $36,850,622, and a shareholders’ deficit of $30,269,888. Management states there is substantial doubt about the company’s ability to continue as a going concern and plans to rely on debt and equity financings, largely from related parties.
All Q1 revenue came from related-party sales, mainly to an affiliate owned by Koze. The company is in default under a security and royalty agreement tied to its main operating subsidiary, and Koze has agreed to forbear exercising its security over that subsidiary until May 31, 2026. Multiple loans to Koze, Mr. Tal and Formosa, royalty obligations, legal disputes, and lapsed insurance further strain liquidity even as the Cremona facility ramps cannabis production and targets European markets.
CannaPharmaRx (CPMD) filed its Q3 2025 report, showing rising sales but continued losses and severe liquidity strain. Revenue reached $656,606 in the quarter (up from $312,164), yet the company posted a gross loss of $440,000 and a net loss of $1,477,811. For the nine months, revenue was $1,223,533 with a net loss of $3,581,863. Cash was $927, total liabilities were $34,133,650, and shareholders’ deficit was $22,516,743. Management disclosed substantial doubt about the company’s ability to continue as a going concern.
On August 7, 2025, the company formalized repayment plans with Koze and affiliates and with Mr. Tal: as of June 30, 2025, about $10 million was owed to Koze and about $0.7 million to Mr. Tal, with interest revised to 6% per annum and 60% of all future profits and capital raised allocated toward repayment. The company is also in default under a royalty/security agreement tied to cannabis sales; Koze agreed to forbear until December 31, 2025. Operations rely on a Formosa lease, with unpaid lease amounts accumulating and a related promissory note now at 6%. Shares outstanding were 662,501,405 as of November 14, 2025.